Literature DB >> 28579913

RAS pathway biomarkers for breast cancer prognosis.

Lauren L Siewertsz van Reesema1, Michael P Lee1, Vasilena Zheleva2, Janet S Winston3, Caroline F O'Connor4, Roger R Perry2, Richard A Hoefer5,6,7, Amy H Tang4,8.   

Abstract

Metastatic breast cancer is a highly heterogeneous, rapidly evolving and devastating disease that challenges our ability to find curative therapies. RAS pathway activation is an understudied research area in breast cancer. EGFR/RAS pathway activation is prevalent in breast cancer with poor prognosis. The prognostic RAS pathway biomarkers can be used to identify resistant tumour clones, stratify patients and guide therapies.

Entities:  

Year:  2016        PMID： 28579913      PMCID： PMC5455995     

Source DB:  PubMed          Journal:  Clin Lab Int        ISSN： 1373-1580


  49 in total

Review 1.  Triple-negative breast cancer.

Authors:  William D Foulkes; Ian E Smith; Jorge S Reis-Filho
Journal:  N Engl J Med       Date:  2010-11-11       Impact factor: 91.245

Review 2.  How genetically engineered mouse tumor models provide insights into human cancers.

Authors:  Katerina Politi; William Pao
Journal:  J Clin Oncol       Date:  2011-01-24       Impact factor: 44.544

Review 3.  Treatment of metastatic breast cancer: state-of-the-art, subtypes and perspectives.

Authors:  Nagi S El Saghir; Arafat Tfayli; Hassan A Hatoum; Zahi Nachef; Phuong Dinh; Ahmad Awada
Journal:  Crit Rev Oncol Hematol       Date:  2011-02-16       Impact factor: 6.312

4.  Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer.

Authors:  Martine J Piccart-Gebhart; Marion Procter; Brian Leyland-Jones; Aron Goldhirsch; Michael Untch; Ian Smith; Luca Gianni; Jose Baselga; Richard Bell; Christian Jackisch; David Cameron; Mitch Dowsett; Carlos H Barrios; Günther Steger; Chiun-Shen Huang; Michael Andersson; Moshe Inbar; Mikhail Lichinitser; István Láng; Ulrike Nitz; Hiroji Iwata; Christoph Thomssen; Caroline Lohrisch; Thomas M Suter; Josef Rüschoff; Tamás Suto; Victoria Greatorex; Carol Ward; Carolyn Straehle; Eleanor McFadden; M Stella Dolci; Richard D Gelber
Journal:  N Engl J Med       Date:  2005-10-20       Impact factor: 91.245

5.  Survival in patients with metastatic recurrent breast cancer after adjuvant chemotherapy: little evidence of improvement over the past 30 years.

Authors:  Amye J Tevaarwerk; Robert J Gray; Bryan P Schneider; Mary Lou Smith; Lynne I Wagner; John H Fetting; Nancy Davidson; Lori J Goldstein; Kathy D Miller; Joseph A Sparano
Journal:  Cancer       Date:  2012-10-12       Impact factor: 6.860

6.  Ras Signaling Is a Key Determinant for Metastatic Dissemination and Poor Survival of Luminal Breast Cancer Patients.

Authors:  Katherine L Wright; Jessica R Adams; Jeff C Liu; Amanda J Loch; Ruth G Wong; Christine E B Jo; Lauren A Beck; Divya R Santhanam; Laura Weiss; Xue Mei; Timothy F Lane; Sergei B Koralov; Susan J Done; James R Woodgett; Eldad Zacksenhaus; Pingzhao Hu; Sean E Egan
Journal:  Cancer Res       Date:  2015-09-23       Impact factor: 12.701

Review 7.  Neoadjuvant chemotherapy in the treatment of breast cancer.

Authors:  Meredith H Redden; George M Fuhrman
Journal:  Surg Clin North Am       Date:  2013-02-11       Impact factor: 2.741

8.  Effect of disrupting seven-in-absentia homolog 2 function on lung cancer cell growth.

Authors:  Atique U Ahmed; Rebecca L Schmidt; Cheol Hong Park; Nanette R Reed; Shayla E Hesse; Charles F Thomas; Julian R Molina; Claude Deschamps; Ping Yang; Marie C Aubry; Amy H Tang
Journal:  J Natl Cancer Inst       Date:  2008-11-11       Impact factor: 13.506

Review 9.  Current approaches and challenges in monitoring treatment responses in breast cancer.

Authors:  Lindsey J Graham; Matthew P Shupe; Erika J Schneble; Frederick L Flynt; Michael N Clemenshaw; Aaron D Kirkpatrick; Chris Gallagher; Aviram Nissan; Leonard Henry; Alexander Stojadinovic; George E Peoples; Nathan M Shumway
Journal:  J Cancer       Date:  2014-01-05       Impact factor: 4.207

10.  Use of a genetically engineered mouse model as a preclinical tool for HER2 breast cancer.

Authors:  Helen Creedon; Lucy A Balderstone; Morwenna Muir; Jozef Balla; Laura Gomez-Cuadrado; Natasha Tracey; Joseph Loane; Teresa Klinowska; William J Muller; Valerie G Brunton
Journal:  Dis Model Mech       Date:  2015-12-31       Impact factor: 5.758
View more
  4 in total

Review 1.  Pumping the brakes on RAS - negative regulators and death effectors of RAS.

Authors:  Desmond R Harrell Stewart; Geoffrey J Clark
Journal:  J Cell Sci       Date:  2020-02-10       Impact factor: 5.285

Review 2.  Risk Factors and Preventions of Breast Cancer.

Authors:  Yi-Sheng Sun; Zhao Zhao; Zhang-Nv Yang; Fang Xu; Hang-Jing Lu; Zhi-Yong Zhu; Wen Shi; Jianmin Jiang; Ping-Ping Yao; Han-Ping Zhu
Journal:  Int J Biol Sci       Date:  2017-11-01       Impact factor: 6.580

Review 3.  Persistent EGFR/K-RAS/SIAH pathway activation drives chemo-resistance and early tumor relapse in triple-negative breast cancer.

Authors:  Amy H Tang; Richard A Hoefer; Mary L Guye; Harry D Bear
Journal:  Cancer Drug Resist       Date:  2022-06-22

4.  Unmet Clinical Need: Developing Prognostic Biomarkers and Precision Medicine to Forecast Early Tumor Relapse, Detect Chemo-Resistance and Improve Overall Survival in High-Risk Breast Cancer.

Authors:  Gagan Gupta; Caroline Dasom Lee; Mary L Guye; Robert E Van Sciver; Michael P Lee; Alex C Lafever; Anthony Pang; Angela M Tang-Tan; Janet S Winston; Billur Samli; Rick J Jansen; Richard A Hoefer; Amy H Tang
Journal:  Ann Breast Cancer Ther       Date:  2020-05-02
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.